Name (Synonyms) | Correlation | |
---|---|---|
drug2481 | Tezepelumab Wiki | 1.00 |
drug520 | Capillary and salivary sampling Wiki | 1.00 |
drug2441 | Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. Wiki | 0.71 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D006969 | Hypersensitivity, Immediate NIH | 1.00 |
D012130 | Respiratory Hypersensitivity NIH | 1.00 |
D006967 | Hypersensitivity, NIH | 0.58 |
D001249 | Asthma NIH | 0.50 |
D007154 | Immune System Diseases NIH | 0.41 |
D008173 | Lung Diseases, Obstructive NIH | 0.33 |
D008171 | Lung Diseases, NIH | 0.26 |
D012140 | Respiratory Tract Diseases NIH | 0.24 |
D007249 | Inflammation NIH | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012393 | Allergy HPO | 0.58 |
HP:0002099 | Asthma HPO | 0.50 |
HP:0006536 | Pulmonary obstruction HPO | 0.33 |
HP:0002088 | Abnormal lung morphology HPO | 0.26 |
There is one clinical trial.
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.
Description: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.
Measure: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies. Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.Description: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies
Measure: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.